Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
DualityBio tries to float again
The group expects to raise nearly $170m.
A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
